UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

PloS one, 2013-05, Vol.8 (5), p.e64268-e64268

2013

Volltextzugriff (PDF)

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment

PloS one, 2015-02, Vol.10 (2), p.e0118346-e0118346

2015

Volltextzugriff (PDF)

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

Breast cancer research and treatment, 2015-02, Vol.149 (3), p.715-726

2015

Volltextzugriff (PDF)

A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells

BMC cancer, 2018-08, Vol.18 (1), p.817-13, Article 817

2018

Volltextzugriff (PDF)

Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells

PloS one, 2014-07, Vol.9 (7), p.e101473-e101473

2014

Volltextzugriff (PDF)

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

International journal of oncology, 2015-04, Vol.46 (4), p.1481-1490

2015

Volltextzugriff (PDF)

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant

Cancer letters, 2014-03, Vol.344 (1), p.90-100

2014

Volltextzugriff (PDF)

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

Endocrine-related cancer, 2008-12, Vol.15 (4), p.985-1002

2008

Volltextzugriff (PDF)

Endocrine potency of wastewater: Contents of endocrine disrupting chemicals and effects measured by in vivo and in vitro assays

Environmental toxicology and chemistry, 2011-02, Vol.30 (2), p.413-426

2011

Volltextzugriff (PDF)

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical cancer research, 2016-11, Vol.22 (22), p.5514-5526

2016

Volltextzugriff (PDF)

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

Journal of clinical pathology, 2007-04, Vol.60 (4), p.397-404

2007

Volltextzugriff (PDF)

A novel dual-target steroid sulfatase inhibitor and antiestrogen : SR 16157, a promising agent for the therapy of breast cancer

Breast cancer research and treatment, 2007-12, Vol.106 (2), p.191-203

2007

Volltextzugriff (PDF)

Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors

Clinical cancer research, 2003-10, Vol.9 (13), p.4961-4971

2003

Volltextzugriff (PDF)

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression

Tumor biology, 2013-12, Vol.34 (6), p.3839-3851

2013

Volltextzugriff (PDF)

1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells

Steroids, 2014-07, Vol.85, p.30-35

2014

Volltextzugriff (PDF)

Altered radiation responses of breast cancer cells resistant to hormonal therapy

Oncotarget, 2015-01, Vol.6 (3), p.1678-1694

2015

Volltextzugriff (PDF)

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling

Breast cancer research and treatment, 2013-05, Vol.139 (1), p.71-80

2013

Volltextzugriff (PDF)

Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties

Breast cancer research : BCR, 2013-12, Vol.15 (6), p.R119-R119, Article R119

2013

Volltextzugriff (PDF)

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells

Breast cancer research and treatment, 2012-08, Vol.135 (1), p.67-78

2012

Volltextzugriff (PDF)

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3

The Journal of steroid biochemistry and molecular biology, 2018-03, Vol.177, p.171-178

2018

Volltextzugriff (PDF)

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D 3

The Journal of steroid biochemistry and molecular biology, 2018-03, Vol.177, p.171

2018

Volltextzugriff (PDF)

Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter—a new regulatory pathway for aromatase

Biochimica et biophysica acta, 2013-01, Vol.1833 (1), p.40-47

2013

Volltextzugriff (PDF)

Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

Molecular cancer therapeutics, 2007-06, Vol.6 (6), p.1869-1876

2007

Volltextzugriff (PDF)

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

Clinical cancer research, 2010-03, Vol.16 (5), p.1486-1497

2010

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(115)

Publikationsform

Artikel
(117)

Sprache

Englisch
(117)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells

Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

Endocrine potency of wastewater: Contents of endocrine disrupting chemicals and effects measured by in vivo and in vitro assays

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

A novel dual-target steroid sulfatase inhibitor and antiestrogen : SR 16157, a promising agent for the therapy of breast cancer

Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors

TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression

1α,25-Dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells

Altered radiation responses of breast cancer cells resistant to hormonal therapy

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling

Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3

Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D 3

Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter—a new regulatory pathway for aromatase

Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

Suchergebnisse filtern